Wang Wear Anti-inflammatory Efficacy Of The Joint Capsule Triple Therapy In Helicobacter Pylori-associated Gastritis Patients

Objective: Helicobacter pylori-associated gastritis is a common clinical disease, the higher the incidence of this disease, and with the changing lifestyles of its upward trend in the incidence of this disease is mainly caused by chronic active gastritis, gastric and digestive ulcers and other diseases caused by clinical treatment is not satisfactory, has been a hot and difficult medical field. In this study, Wang wear anti-inflammatory joint capsule triple therapy Helicobacter pylori-associated gastritis, inflammation king wearing explore joint capsule triple therapy clinical results provide evidence for the clinical treatment of Helicobacter pylori-associated gastritis.Methods: The author hospital diagnosis, Helicobacter pylori-associated gastritis patient-related data to analyze the treatment of 150 cases, according to the different treatment methods will be divided into two groups, the control group with triple therapy, the experimental group wore the king inflammatory joint capsule treatment, two patients are seven days for a course of treatment. And clinical symptoms were observed before and after treatment were recorded once, four weeks after the end of treatment for patients with 14 C breath test, HP eradication rates observed in patients with clinical improvement of symptoms, the use of daily living scale(ADL) and a comprehensive assessment of the quality of life questionnaire(GQOL-74)quality of life for the two groups were evaluated and analyzed for drug complications in patients after treatment.Results: 97.3% of patients in the experimental group treatment program affirmed the assessment was higher(89.3%)(P <0.05); the experimental group 93.3% of patients on therapy results were satisfactory, the control group(P <0.05); the experimental group therapy after the clinical symptoms(2.52 ± 1.92) points lower than in the control group(4.68 ± 3.13) min(P <0.05); the experimental group after drug treatment eradication rate was 90.67%, higher than that(49 cases of successful eradication, eradication rate to 65.33%)(P <0.05); the two groups before treatment difference was not significant(P> 0.05); the experimental group after treatment PRO score was(61.40 ± 15.60) points, significantly lower than the control group(PRO score was 61.40 ± 15.60 for) points; PHO integral experimental group before and after treatment difference(16 ± 7.56) points, significantly higher(9.25 ± 13.98) min(P <0.05); ADL scores for the experimental group(16.2 ± 3.7) points, physical function score was(59.6±7.5) points, psychological function score was(65.8 ± 9.2) points, social function score was(57.2±6.5) points, were higher(P <0.05); the experimental group, the incidence of adverse drug reactions 5.33 %, lower than the control group(incidence of adverse reactions 37.5%)(x2 = 5.81, P<0.05).conclusion:1, Wang wear anti-inflammatory joint capsule triple therapy for Helicobacter pylori-associated gastritis is an ideal treatment method of treatment, can effectively improve symptoms, alleviate the patient’s condition.2, Wang wear anti-inflammatory joint capsule triple therapy Helicobacter pylori-related gastritis can play different therapeutic advantage drugs, do complement each other, effectively improve the clinical cure rate and improvethe quality of life of patients.3, wearing a king-inflammatory capsules combined with conventional Western medicine treatment can improve the efficacy of sequential therapy, but also for the current anti-Helicobacter pylori treatment of multidrug resistance to find new solutions, worthy of study and promotion.